Thoratec® Reports Second Quarter 2014 Results - Revenue of $118.1 million for the second quarter of 2014

- GAAP Net Income per Diluted Share of $0.30, and Non-GAAP Net Income per Diluted Share of $0.43

- Company adjusts full-year 2014 guidance for revenue to a range of $455 million to $470 million and for net income per diluted share to $0.80 to $0.90 on a GAAP basis and $1.25 to $1.35 on a non-GAAP basis

- HeartMate III™ and HeartMate PHP™ begin CE Mark Trials; FDA grants conditional approval to start HeartMate III U.S. IDE trial

PLEASANTON, Calif., Aug. 6, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported its financial results for the second quarter and first half of 2014.

"We are disappointed with the shortfall in our financial results as near-term factors are having a greater than expected negative impact on our business," said Gary F. Burbach, President and Chief Executive Officer.  "However, our confidence in the long-term outlook for our business remains unchanged, and we will focus on executing to realize these opportunities while working diligently on implementing actions to improve near-term results," he added.

For the quarter ended June 28, 2014, Thoratec reported revenues of $118.1 million, a ten percent decrease versus revenues of $130.5 million in the same period a year ago.  Net income on a GAAP basis was $17.4 million, or $0.30 per diluted share, compared to GAAP net income of $23.2 million, or $0.40 per diluted share, in the same period last year.  Non-GAAP net income, which is described later in this press release, was $24.4 million, or $0.43 per diluted share in the second quarter of 2014, compared to non-GAAP net income of $30.4 million, or $0.52 per diluted share, in the second quarter of 2013.

For the first six months of fiscal 2014, revenues were $243.8 million, a decrease of two percent over revenues of $248.2 million in the same period a year ago.  Net income on a GAAP basis was $35.7 million, or $0.62 per diluted share, compared with GAAP net income of $41.4 million, or $0.71 per diluted share, in the same period a year ago.  Non-GAAP net income was $48.1 million, or $0.84 per diluted share, compared with non-GAAP net income of $54.3 million, or $0.93 per diluted share, in the same period a year ago.

"We have realized significant clinical progress in our pipeline opportunities with encouraging starts of CE Mark trials for both HeartMate III and HeartMate PHP, while HeartMate III also received conditional approval from FDA to begin the U.S. trial," Burbach commented.  "Moreover, the accelerated share repurchase announced today reflects conviction in our long-term vision, and our strong financial position will allow us to continue funding future growth initiatives, strategic investments, and share repurchases going forward."

Second Quarter and First Six Months of 2014 Financial Results

Thoratec reported revenues of $118.1 million in the second quarter of 2014, a decrease of ten percent compared to the same quarter last year.  The HeartMate® product line contributed $102.0 million, a decrease of 12 percent while the CentriMag product line contributed $13.1 million, an increase of 14 percent.

For the first half of 2014, Thoratec reported revenues of $243.8 million, a decrease of two percent, compared to the same period last year.  The HeartMate product line contributed $212.0 million to revenues, while the CentriMag product line contributed $26.1 million.

GAAP gross margin in the second quarter of 2014 was 70.9 percent compared to 68.6 percent in the same quarter last year.  Non-GAAP gross margin, described later in this press release, was 72.4 percent compared to 70.4 percent in the same quarter last year.  The increase in GAAP and non-GAAP gross margin was due primarily to favorable manufacturing absorption variances and underlying efficiencies, offset in part by unfavorable warranty expense and inventory reserves.  In addition, GAAP gross margin was positively affected by lower intangible assets amortization expense.

GAAP operating expenses in the second quarter of 2014 were $58.5 million compared to $56.4 million in the same quarter last year.  Non-GAAP operating expenses, described later in this press release, were $50.3 million compared to $47.7 million in the same quarter last year.  The increase in both GAAP and non-GAAP operating expenses was primarily due to incremental expenses from the DuraHeart II program acquired during the third quarter of 2013 and the timing of sales and marketing initiatives, partially offset by a reduction in incentive compensation expense. 

The company's GAAP effective tax rate in the second quarter of 2014 was 32.5 percent versus 30.3 percent a year ago.  The non-GAAP tax rate, which is described later in this press release, was 32.0 percent versus 31.5 percent in the same period last year.  The increase in both the GAAP and non-GAAP effective tax rates was primarily due to the lack of federal R&D credits in the absence of enacted legislation. 

Cash and investments were $295.5 million as of June 28, 2014, compared to $299.4 million as of March 29, 2014, and $310.0 million as of December 28, 2013.  The company repurchased approximately $25 million of stock during the second quarter of 2014.  Earlier in the third quarter, the company funded the $35 million purchase of Apica Cardiovascular using existing cash balances.

GUIDANCE FOR FISCAL 2014

The following statements are based on current expectations.  These statements are forward-looking and actual results may differ materially.  For a more detailed discussion of forward-looking statements, please see the additional information below. 

The company is revising fiscal 2014 guidance for revenues to a range of $455 million to $470 million and net income per diluted share of $0.80 to $0.90 on a GAAP basis and $1.25 to $1.35 on a non-GAAP basis.  Gross margin is expected to be approximately 69 percent on a GAAP basis and 70.5 percent on a non-GAAP basis.  We expect the effective tax rate to be approximately 31 percent on both a GAAP and non-GAAP basis.  The guidance above does not include any impact from the Apica Cardiovascular acquisition's purchase price allocation, which has not yet been finalized; however, this purchase price allocation should not affect results on a non-GAAP basis.

CONFERENCE CALL/WEBCAST INFORMATION

Thoratec will hold a conference call to discuss its financial results and operating activities for all interested parties at 1:30 p.m., Pacific Daylight Time (4:30 p.m., Eastern Daylight Time), today. The teleconference can be accessed by calling (719) 457-2653, passcode 9016109.  Please dial in 10-15 minutes prior to the beginning of the call.  The webcast will be available via the Internet at http://www.thoratec.com.  A replay of the conference call will be available through Wednesday, August 13, via http://www.thoratec.com or by telephone at (719) 457-0820, passcode 9016109.

GAAP TO NON-GAAP RECONCILIATION

Thoratec management evaluates and makes operating decisions using various measures. These measures are generally based on revenues generated by the company's products and certain costs of producing those revenues, such as costs of product sales, research and development and selling, general and administrative expenses. We use the following measures, which are not calculated in accordance with Generally Accepted Accounting Principles ("GAAP"): non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP tax rate, non-GAAP net income, and non-GAAP net income per diluted share. These are non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. These non-GAAP financial measures are calculated by excluding certain GAAP financial items that we believe have less significance to the day-to-day operation of our business.  The company has outlined below the type and scope of these exclusions and the limitations on the use of the non-GAAP financial measures as a result of these exclusions.

Management uses these non-GAAP financial measures for financial and operational decision making, including in the determination of employee annual cash incentive compensation, as a means to evaluate period-to-period comparisons, as well as comparisons to our competitors' operating results.  Management also uses this information internally for forecasting and budgeting, as it believes that the measures are indicative of Thoratec's core operating results.  Management also believes that non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the company's business operations, provide a greater transparency with respect to key metrics used by management in its decision making, facilitate comparisons of results for current periods and guidance for future periods with our historical operating results, and assist in analyzing future trends.

Non-GAAP net income consists of GAAP net income, excluding, as applicable, the tax-effected impact of share-based compensation expense, the amortization of purchased intangible assets, acquisition-related contingent consideration adjustments, and acquisition-related transaction costs.

Non-GAAP net income per diluted share is defined as non-GAAP net income divided by the weighted average number of shares on a fully-diluted basis. 

Non-GAAP gross profit and gross margin consist of GAAP gross profit and gross margin excluding share-based compensation expense and the amortization of purchased intangible assets.   

Non-GAAP operating expenses consist of GAAP operating expenses excluding share-based compensation expense, the amortization of purchased intangible assets, acquisition-related contingent consideration adjustments, and acquisition-related transaction costs.

Non-GAAP tax expense consists of the GAAP tax expense adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income.

Management believes that it is useful in measuring Thoratec's operations to exclude the amortization of purchased intangible assets.  These costs are primarily fixed at the time of an acquisition and, unlike other fixed costs that result from ordinary operations, are the result of infrequent and irregular events.

Because of varying valuation methodologies, subjective assumptions and the variety of award types that companies can use, Thoratec management believes that providing non-GAAP financial measures that exclude share-based compensation allows investors to compare Thoratec's recurring core business operating results to those of other companies and over multiple periods.  The exclusion also enhances investors' ability to review Thoratec's business from the same perspective as Thoratec management, which believes that share-based compensation expense is not directly attributable to the underlying performance of the company's business operations.

Thoratec management has excluded acquisition-related contingent consideration adjustments and acquisition-related transaction costs from GAAP results to allow investors to compare Thoratec's recurring core business operating results to those of other companies and over multiple periods.

There are a number of limitations related to the use of non-GAAP financial measures.  First, non-GAAP financial measures exclude some costs, namely share-based compensation, that are recurring expenses.  Second, share-based compensation is part of an employee's compensation package and as such may be useful for investors to consider.  Third, the components of costs that we exclude in our non-GAAP financial measures may differ from components that our peer companies exclude when they report their results from operations.

Non-GAAP financial measures should not be considered as a substitute for measures of financial performance in accordance with GAAP. However, these measures may provide additional insight into Thoratec's financial results. Investors and potential investors are strongly encouraged to review the reconciliation of non-GAAP financial measures contained within this press release with their most directly comparable GAAP financial results and not to rely on any single financial measure to evaluate our business.

The reconciliations of the forward looking non-GAAP financial measures to the most directly comparable GAAP financial measures in the tables below include all information reasonably available to Thoratec at the date of this press release.  These tables include adjustments that we can reasonably predict.  Events that could cause the reconciliation to change include acquisitions and divestitures of business, goodwill and other asset impairments and sales of marketable equity securities.

The following table includes the GAAP condensed consolidated balance sheets as of June 28, 2014 and December 28, 2013:

THORATEC CORPORATION

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands)










June 28, 2014


December 28, 2013

ASSETS




Current assets:




Cash and cash equivalents 

$          134,729


$                139,099

Short-term available-for-sale investments 

156,472


166,691

Receivables, net of allowances of $1,976 in 2014 and $2,163 in 2013 

68,648


71,418

Inventories 

67,367


60,293

Deferred tax assets 

15,161


15,161

Income tax receivable 

12,353


5,733

Prepaid expenses and other assets 

7,335


7,272

Total current assets 

462,065


465,667

Property, plant and equipment, net 

55,970


55,163

Goodwill 

205,955


205,764

Purchased intangible assets, net 

32,602


36,403

Long-term available-for-sale investments 

4,270


4,234

Other long-term assets 

25,385


24,476

Total Assets 

$          786,247


$                791,707

LIABILITIES AND SHAREHOLDERS' EQUITY




Current liabilities:




Accounts payable 

$            18,239


$                  17,599

Accrued compensation 

14,338


22,759

Contingent liabilities, current portion 

9,750


6,962

Other accrued liabilities 

26,912


27,001

Total current liabilities 

69,239


74,321

Long-term deferred tax liability 

1,793


2,224

Other long-term liabilities 

12,779


12,105

Contingent liabilities, non-current portion

25,198


36,384

Total Liabilities 

109,009


125,034

Shareholders' equity:




Common shares: no par, authorized 100,000; issued and outstanding 56,332 in 2014 and 56,904 in 2013 

-


-

Additional paid-in-capital 

626,501


621,589

Retained earnings 

63,969


57,587

    Accumulated other comprehensive loss

(13,232)


(12,503)

Total Shareholders' Equity 

677,238


666,673

Total Liabilities and Shareholders' Equity 

$          786,247


$                791,707

The following table includes the GAAP Condensed Consolidated Statements of Operations for the three and six month periods ending June 28, 2014 and June 29, 2013:


THORATEC CORPORATION

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except for per share data)





















 Three Months Ended 


 Six Months Ended 



June 28, 2014


June 29, 2013


June 28, 2014


June 29, 2013










Product sales


$       118,063


$       130,479


$       243,760


$       248,204

Cost of product sales


34,307


41,000


74,333


76,073

Gross profit


83,756


89,479


169,427


172,131

Operating expenses:









Selling, general and administrative


35,477


34,924


70,978


69,669

Research and development


23,048


21,506


46,387


46,019

Total operating expenses


58,525


56,430


117,365


115,688

Income from operations


25,231


33,049


52,062


56,443

Other income and (expense):









Interest expense


(2)


0


(2)


(4)

Interest income and other


559


213


806


1,330

Income before income taxes


25,788


33,262


52,866


57,769

Income tax expense 


(8,375)


(10,073)


(17,214)


(16,410)

Net income


$         17,413


$         23,189


$         35,652


$         41,359



















Net income per share- Basic:


$             0.31


$             0.40


$             0.63


$             0.72










Net income per share- Diluted:


$             0.30


$             0.40


$             0.62


$             0.71










Shares used to compute net income per share:









Basic


56,723


57,429


56,781


57,457

Diluted


57,188


58,120


57,538


58,398

The following table presents our quarterly revenues by source for the first and second quarter of fiscal 2014 and for the full year of fiscal 2013:

THORATEC CORPORATION

Quarterly Revenue Analysis

(Unaudited)

(in millions)






































 Three Months Ended 


June 28, 2014


March 29, 2014


December 28, 2013


September 28, 2013


June 29, 2013


March 30, 2013













Revenue by Product Line












HeartMate

$           102.0


$              110.0


$                    113.0


$                     112.8


$           115.7


$              102.9

CentriMag (1)

13.1


13.0


11.0


10.4


11.5


10.4

PVAD & IVAD

2.5


2.3


3.4


2.6


2.7


3.8

Other

0.5


0.4


0.8


0.6


0.6


0.6

Total

$           118.1


$              125.7


$                    128.2


$                     126.4


$           130.5


$              117.7













Revenue by Category












Pump

$             81.6


$                89.3


$                      90.4


$                       87.1


$             93.5


$                84.3

Non-Pump

36.0


36.0


37.0


38.7


36.4


32.8

Other

0.5


0.4


0.8


0.6


0.6


0.6

Total

$           118.1


$              125.7


$                    128.2


$                     126.4


$           130.5


$              117.7













Revenue by Geography












United States

$             94.2


$                95.6


$                      99.8


$                       99.6


$             98.8


$                92.3

International

23.9


30.1


28.4


26.8


31.7


25.4

Total

$           118.1


$              125.7


$                    128.2


$                     126.4


$           130.5


$              117.7













(1) CentriMag includes PediMag/PediVAS®  sales









The following table presents our quarterly HeartMate pump units by geography for the first and second quarter of fiscal 2014 and for the full year of fiscal 2013:

THORATEC CORPORATION

Quarterly Heartmate Pump Units (1)

(Unaudited)





























Three Months Ended

Units by Geography


June 28, 2014


March 29, 2014


December 28, 2013


September 28, 2013


June 29, 2013


March 30, 2013

United States


670


701


733


713


748


689

International


193


263


240


241


277


205

Total (1)


863


964


973


954


1,025


894



























(1) Excludes CentriMag, PediMag/PediVAS and PVAD/IVAD units







The following table reconciles the specific items excluded from GAAP net income in the calculation of non-GAAP net income and diluted net income per share for the periods shown below:


THORATEC CORPORATION

Reconciliation of GAAP to Non-GAAP Net Income

(Unaudited)

(in thousands, except for per share data)





















 Three Months Ended 


 Six Months Ended 

Net income reconciliation


June 28, 2014


June 29, 2013


June 28, 2014


June 29, 2013










Net income on a GAAP basis


$         17,413


$         23,189


$         35,652


$         41,359

Share-based compensation expense:









- Cost of product sales


756


616


1,377


1,187

- Selling, general and administrative


4,794


4,625


8,819


8,308

- Research and development


2,283


1,964


4,419


3,878

Amortization of purchased intangibles:









- Cost of product sales


1,016


1,703


2,029


3,417

- Selling, general and administrative


765


748


1,526


1,500

- Research and development


132


82


264


164

Acquisition-related contingent consideration adjustments:









- Selling, general and administrative


(377)


-


712


-

- Research and development


(593)


-


(2,148)


-

Acquisition-related transaction costs


1,271


1,344


1,271


1,344

Income tax effect of non-GAAP adjustments


(3,092)


(3,900)


(5,839)


(6,830)

Net income on a non-GAAP basis


$         24,368


$         30,371


$         48,082


$         54,327












 Three Months Ended 


 Six Months Ended 

Diluted net income per share reconciliation


June 28, 2014


June 29, 2013


June 28, 2014


June 29, 2013










Diluted net income per share on a GAAP basis


$             0.30


$             0.40


$             0.62


$             0.71

Share-based compensation expense:









- Cost of product sales


0.01


0.01


0.02


0.02

- Selling, general and administrative


0.09


0.08


0.15


0.14

- Research and development


0.04


0.04


0.08


0.07

Amortization of purchased intangibles:









- Cost of product sales


0.02


0.03


0.04


0.06

- Selling, general and administrative


0.01


0.01


0.03


0.03

- Research and development


0.00


0.00


0.01


0.00

Acquisition-related contingent consideration adjustments:









- Selling, general and administrative


(0.00)


-


0.01


-

- Research and development


(0.01)


-


(0.04)


-

Acquisition-related transaction costs


0.02


0.02


0.02


0.02

Income tax effect of non-GAAP adjustments


(0.05)


(0.07)


(0.10)


(0.12)

Diluted net income per share on a non-GAAP basis


$             0.43


$             0.52


$             0.84


$             0.93












 Three Months Ended 


 Six Months Ended 



June 28, 2014


June 29, 2013


June 28, 2014


June 29, 2013

Shares used to compute diluted net income per share reconciliation


















Shares used in calculation of diluted net income per share -- GAAP and non-GAAP


57,188


58,120


57,538


58,398

The following table reconciles the specific items excluded from GAAP gross profit and gross margin in the calculation of non-GAAP gross profit and gross margin for the periods shown below:

THORATEC CORPORATION


Reconciliation of GAAP to Non-GAAP Gross Profit


(Unaudited)


(in thousands)























 Three Months Ended 



 Six Months Ended 



June 28, 2014


June 29, 2013



June 28, 2014


June 29, 2013












Gross profit on a GAAP basis

$         83,756

70.9%

$         89,479

68.6%


$       169,427

69.5%

$       172,131

69.4%

Share-based compensation expense

756


616



1,377


1,187


Amortization of intangibles

1,016


1,703



2,029


3,417


Gross profit on a non-GAAP basis

$         85,528

72.4%

$         91,798

70.4%


$       172,833

70.9%

$       176,735

71.2%

The following table reconciles the specific items excluded from GAAP operating expenses in the calculation of non-GAAP operating expenses for the periods shown below:  


THORATEC CORPORATION

Reconciliation of GAAP to Non-GAAP Operating Expenses

(Unaudited)

(in thousands)





















 Three Months Ended 


 Six Months Ended 



June 28, 2014


June 29, 2013


June 28, 2014


June 29, 2013










 Operating expenses on a GAAP basis 


$         58,525


$         56,430


$       117,365


$       115,688

Share-based compensation expense:









- Selling, general and administrative


(4,794)


(4,625)


(8,819)


(8,308)

- Research and development


(2,283)


(1,964)


(4,419)


(3,878)

Amortization of purchased intangibles:









- Selling, general and administrative


(765)


(748)


(1,526)


(1,500)

- Research and development


(132)


(82)


(264)


(164)

Acquisition-related contingent consideration adjustments:







- Selling, general and administrative


377


-


(712)


-

- Research and development


593


-


2,148


-

Acquisition-related transaction costs


(1,271)


(1,344)


(1,271)


(1,344)

 Operating expenses on a non-GAAP basis 


$         50,250


$         47,667


$       102,502


$       100,494

The following table reconciles the GAAP tax expense adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income:

THORATEC CORPORATION


Reconciliation of GAAP to Non-GAAP Tax Expense


(Unaudited)


(in thousands)













 Three Months Ended 



 Six Months Ended 



June 28, 2014


June 29, 2013



June 28, 2014


June 29, 2013












Tax expense on a GAAP basis

$           8,375

32.5%

$         10,073

30.3%


$         17,214

32.6%

$         16,410

28.4%

Share-based compensation expense

2,949


2,493



5,228


4,529


Amortization of purchased intangibles

650


892



1,298


1,786


Acquisition-related contingent consideration adjustments

(996)


-



(1,176)


-


Acquisition-related transaction costs

489


515



489


515


Tax expense on a non-GAAP basis

$         11,467

32.0%

$         13,973

31.5%


$         23,053

32.4%

$         23,240

30.0%

The following table reconciles the guidance on a GAAP basis and non-GAAP basis for the periods shown below: 


THORATEC CORPORATION

Reconciliation of GAAP to Non-GAAP  Forward-Looking Guidance

(Unaudited)

(in thousands, except for per share data)






Gross margin


 For the Fiscal Year 2014 








Gross margin on a GAAP basis


69.0%



Amortization of purchased intangibles


0.9%



Share-based compensation expense


0.6%



Gross margin on a non-GAAP basis


70.5%








Net income per diluted share reconciliation

 For the Fiscal Year 2014 



From


To







Net income per diluted share on a GAAP basis

$     0.80


$      0.90


Share-based compensation expense

0.36


0.36


Amortization of purchased intangibles

0.09


0.09


Acquisition-related contingent consideration adjustments

(0.01)


(0.01)


Acquisition-related transaction costs

0.02


0.02


Tax rate effect on non-GAAP earnings

(0.01)


(0.01)


Net income per diluted share on a non-GAAP basis

$     1.25


$      1.35







Shares used in calculation of net income per diluted share - GAAP and non-GAAP

57,000


57,000


About Thoratec

Thoratec is a world leader in therapies to address advanced-stage heart failure.  The company's products include the HeartMate II® LVAS (Left Ventricular Assist Systems) and Thoratec® VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures the CentriMag® and PediMag®/PediVAS® product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's website at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and HeartMate III, HeartMate PHP, PVAD, IVAD and Pocket Controller are trademarks of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.

DuraHeart is a registered trademark of Terumo Corporation.

Many of the preceding paragraphs, particularly but not exclusively those addressing guidance for fiscal 2014 financial results or future performance contain forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "anticipates, " "plans," "projects," "should," "hopes," "could," "will," "estimates," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new products, including development and clinical trial timing, and new markets including Destination Therapy, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, changes in the mix of existing markets for our products and related gross margin for such product sales, the ability to improve financial performance, the effects of FDA regulatory requirements, our ability to address quality issues adequately and on a timely basis without a resulting recall of products or interruption of manufacturing or shipment of products, the effects of healthcare reimbursement and coverage policies, the effects of seasonality on Thoratec product sales, the effects of competition and the effects of any merger, acquisition and divestiture related activities. Forward-looking statements contained in this press release should be considered in light these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events. 

SOURCE Thoratec Corporation



RELATED LINKS
http://www.thoratec.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.